The legislature's own summary of the bill, or its official long title.
The bill states that the Colorado prescription drug affordability review board has no authority to perform an affordability review of, or to establish an upper payment limit for, a prescription drug that is: Designated as a drug for a rare disease or condition by the food and drug administration (FDA) of the federal department of health and human services; or A licensed biological product that is derived from human whole blood or plasma as indicated on product labeling approved by the FDA. (Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)
Every action
8 steps, oldest first, as the legislature records them.
CommitteeIntroduced In Senate - Assigned to Health & Human Services · Senate Health & Human Services
CommitteeSenate Committee on Health & Human Services Refer Unamended to Senate Committee of the Whole · Senate Health & Human Services
SenateSenate Second Reading Laid Over to 04/09/2026 - No Amendments
SenateSenate Second Reading Passed - No Amendments
SenateSenate Third Reading Laid Over to 04/13/2026 - No Amendments
SenateSenate Third Reading Passed - No Amendments
CommitteeIntroduced In House - Assigned to Health & Human Services · House Health & Human Services
CommitteeHouse Committee on Health & Human Services Postpone Indefinitely · House Health & Human Services
Roll calls
3 recorded votes: 1 on the floor, 2 in committee. Each shows how every member voted.